Article

Launch Sequencing of Pharmaceuticals with Multiple Therapeutic Indications: Evidence from Seven Countries

2022-08-25

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>. New medicines are increasingly being identified as efficacious across multiple indications. The impact of current pricing and reimbursement policies on launch decisions across these indications remains unclear. <bold>Objective</bold>. This paper, first, maps marketing authorisation (MA) and HTA coverage recommendation sequences of multi-indication medicines acro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 13908bcc-83aa-5e98-866f-b98d9216739c
DOI: 10.21203/rs.3.rs-1953565/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Launch Sequencing of Pharmaceuticals with Multiple Therapeutic Indications: Evidence from Seven CountriesDOI 10.21203/rs.3.rs-1953565/v1Read

A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within EU Between 2011 and 2020Semantic proximity Read

U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity Read

Time to Patients’ Access to New Medicines in Greece: Evaluation of Health Technology Assessment (HTA) Process from July 2018 until January 2021.Semantic proximity Read

Quantifying hope: An EU perspective of rare disease therapeutic space and market dynamicsSemantic proximity Read

Calendar Period Estimation of Probabilities of Transition in Drug DevelopmentSemantic proximity Read

Global Inequities in Precision Oncology Drug Development: A Cross-Sectional Analysis of FDA Approvals Between 2017-2024Semantic proximity Read

How the HTAR will contribute to a value-based decision making for medicinal products across the EUSemantic proximity Read

Analysis of Patient Access to Orphan Drugs in TurkeySemantic proximity Read

Access to Essential and Innovative Anti-cancer Medicines: A Longitudinal Study in Nanjing, ChinaSemantic proximity Read

Development Analysis and Strategic Insights from a 505(b)(2) Reformulation Product: EnzalutamideSemantic proximity Read

Developing Generic Templates to Shape the Future for Conducting Integrated Research Platform TrialsSemantic proximity Read

Trend of clinical trials of new drugs for rare diseases in China in recent 10 yearsSemantic proximity Read